Arizona and Taiwan Sign MOU to Foster Bilateral Biotech Exchange and Collaboration

On June 23, 2026, during the BIO International Convention (BIO 2026), the Arizona Bioindustry Association (AZBio) and the Taiwan Bio Industry Organization (Taiwan BIO) jointly signed a Memorandum of Understanding (MOU), marking a new milestone in bilateral life sciences collaboration. The core objective of this agreement is to establish cross-border communication channels between the biotech communities of both regions, promote industrial innovation and the sharing of resources, thus fostering partnerships that deliver mutual benefits. 

The event brought together over 100 representatives from the Taiwanese and American biotech sectors, including industry leaders, government officials, academics and researchers, celebrating this special moment. Participants expressed hope that the complementarity of resources from both sides would catalyze more pioneering biotech breakthroughs and business opportunities.

Deepening 5-year Collaboration to Address Pain Points in Biotech Startups

Joan Koerber-Walker, President and CEO of AZBio, noted that the cooperation and technology exchange between Arizona and Taiwan in the biotech sector have been ongoing for more than five years. The signing of this MOU represents a key step to formalize and institutionalize the existing partnerships.

Koerber-Walker also noted that biotech innovators typically encounter two significant hurdles: the difficulty of locating compatible international partners and the struggle to obtain sufficient funding for early-stage R&D. The new bilateral alliance aims to address these issues directly by broadening collaborative networks and pooling resources. Through this strategic partnership, both regions intend to bypass growth limitations, expedite the creation of innovative therapies, and drive sustainable economic progress alongside improvements in global health.

Distinguished Officials Witness the New Chapter in U.S.-Taiwan Biotech Ties

During his address to Arizona representatives, Taiwan BIO’s Chairman Lee-Cheng Liu highlighted the strategic importance and future prospects of Taiwan’s biotechnology sector, drawing a parallel to TSMC’s expansion in the United States. He pointed out the increasing number of top-tier Taiwanese professionals relocating to Phoenix, Arizona’s capital, to establish their careers and lives. This partnership seeks to utilize the combined technological and human resource advantages of both regions to achieve meaningful advancements in public health and community prosperity.

The event culminated in the formal signing of the MOU, an occasion overseen by a distinguished panel of four government officials. Following the signing, delegates from both regions gathered for a commemorative group photograph. The official witnesses for the ceremony were: Ryan Touhill, Director of Community and Economic Development for the City of Phoenix; Yu-Chun Lin, Section Chief at the Industrial Development Administration, Ministry of Economic Affairs; Christine Mackay, President and CEO of the Greater Phoenix Economic Council (GPEC); and Sara Chen, Deputy Director General of the Taipei Economic and Cultural Office in Los Angeles.

The Strengths of Taiwan’s Biotech Industry Revealed

Advancements in biomedical sciences and health technology seldom occur in isolation. Rather, significant breakthroughs are built upon a foundation of international trust, enduring strategic alliances, and persistent cross-border cooperation. Capitalizing on its renowned medical expertise and powerful industrial infrastructure, Taiwan has solidified its role as a dependable ally within the international life sciences community.

For BIO 2026, Taiwan’s involvement centers on the theme “Taiwan: Your Best Partner in Asia.” According to Yu-Chun Lin, Section Chief at the Industrial Development Administration, Ministry of Economic Affairs, and Sara Chen, Deputy Director General of the Taipei Economic and Cultural Office in Los Angeles, Taiwan stands out for its top-tier talent pool, robust healthcare system, strong R&D capabilities, transparent regulatory framework, and rigorous intellectual property protection—all of which create a favorable and competitive investment environment. By integrating its semiconductor leadership with the biotech excellence, Taiwan is establishing itself as a reliable gateway and strategic center for global biopharma players aiming to grow within the Asia-Pacific region.

Taiwan’s life sciences ecosystem thrives across multiple sectors, encompassing drug discovery, novel therapeutics, high-end medical devices, in vitro diagnostics (IVD), digital health, and CDMO, demonstrating strong capabilities in vertically integrated R&D and manufacturing. For its participation in the BIO 2026, Taiwan assembled a large delegation featuring over 200 industry leaders, academic experts, and government officials, underscoring its commitment to advancing the global biotech and healthcare landscape and strengthening supply chain ties with the United States.

BIO Asia-Taiwan 2026, a Catalyst for Cross-border Innovations

BIO Asia-Taiwan 2026, scheduled for this July in Taipei, has garnered substantial acclaim and interest from the global biotechnology sector during BIO 2026. Mackensie Vernetti, Senior Vice President of Partnering at the Biotechnology Innovation Organization (BIO), noted that the event’s One-on-One Partnering platform experienced an immediate surge in activity following its launch. With over 1,000 meeting requests already submitted by international delegates, the high volume of early engagement reflects the global community’s strong expectations for the Asian market and Taiwan’s biotech landscape.

The establishment of the Arizona-Taiwan MOU is expected to drive further collaboration at the event, encouraging increased participation from investment firms and biotech enterprises based in the U.S. Southwest. This strategic alliance aims to leverage the upcoming BIO Asia-Taiwan 2026 summit as a catalyst for transformative cross-border biomedical innovations.

Author

Richard Chau